RNA
Atrium Therapeutics, Inc. Common Stock
NASDAQ: RNA · HEALTHCARE · BIOTECHNOLOGY
$12.99
+3.51% today
Updated 2026-04-29
Market cap
$201.54M
P/E ratio
—
P/S ratio
10.82x
EPS (TTM)
$-4.48
Dividend yield
—
52W range
$12 – $17
Volume
1.5M
Atrium Therapeutics, Inc. Common Stock (RNA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | — | $-9.65M | $2.49M | $-37.12M | $-94.81M | $-136.27M | $-119.06M | $-300.87M | $-41.13M |
| Capital expenditures | $2.60M | $309000.00 | $834000.00 | $49000.00 | $235000.00 | $1.09M | $3.74M | $2.82M | $4.23M | $7.07M | $1.45M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | $60000.00 | $406000.00 | $4.31M | $17.06M | $27.14M | $38.22M | $51.36M | $7.68M |
| Free cash flow | — | — | — | $-9.70M | $2.25M | $-38.21M | $-98.55M | $-139.09M | $-123.29M | $-307.94M | $-42.57M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $106000.00 | $106000.00 | $444000.00 | $0.00 | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — |